Collaboration Between Sonrai and AOA Dx Speeds Up Progress in Creating an Ovarian Cancer Diagnostic Test
In a groundbreaking move, Sonrai Analytics and AOA Dx have announced a strategic partnership aimed at accelerating the development of AOA's innovative diagnostic test for ovarian cancer. This test leverages a unique combination of novel gangliosides, lipids, and proteins.
The collaboration will see AOA leverage Sonrai's cloud-based advanced analytics platform, data infrastructure, and bioinformatic expertise. This partnership aims to advance the development through a multi-omic biomarker validation strategy.
Sonrai's platform specializes in integrating complex genomic and multi-omic data. This enables the comprehensive analysis of AOA Dx’s diverse biological data obtained from the liquid biopsy. Sonrai applies machine learning algorithms and AI-driven insights to identify meaningful biomarker patterns and improve the accuracy and sensitivity of ovarian cancer detection in early and late stages.
By automating and accelerating data processing and interpretation, the partnership reduces development timelines, enabling quicker progression from research to clinical validation and commercialization. The collaboration also aims to refine and validate predictive biomarker signatures critical to the multi-omic test, thus optimizing test performance.
Prof. Darragh McArt, CEO and Founder of Sonrai Analytics, expressed delight at partnering with AOA Dx to help advance the development of their innovative test for ovarian cancer. The Sonrai Discovery platform will enable AOA to store and manage their clinical data securely, ensuring compliance and governance.
Dr Abigail McElhinny, Chief Scientific Officer of AOA Dx, stated that by partnering with Sonrai, they can integrate and manage their in-house development data and cross-reference it with public datasets within one centralized environment. This combination is critical to both AOA Dx's research and regulatory approval process.
Elsewhere, AbbVie has received marketing authorisation from the MHRA, while Dxcover has strengthened its leadership with the addition of world-class scientific advisors and board members.
Diagnosing women when symptoms first occur could transform the pathway for women, potentially changing outcomes and offering significant savings to healthcare systems. The development of a reliable, scalable, and ready-for-clinical-use ovarian cancer liquid biopsy test is a significant step towards this goal.
1) This strategic partnership between Sonrai Analytics and AOA Dx, focused on ovarian cancer detection, utilizes Sonrai's digital health platform, which integrates complex genomic and multi-omic data, to advance the development through a multi-omic biomarker validation strategy.
2) By applying machine learning algorithms and AI-driven insights, Sonrai's technology aims to improve the accuracy and sensitivity of ovarian cancer detection in early and late stages, potentially revolutionizing health-and-wellness for women.
3) The collaboration between AOA Dx and Sonrai also involves integrating and managing AOA's in-house development data within one centralized environment, combining it with public datasets, a crucial step in their research and regulatory approval process.
4) Leveraging the power of artificial-intelligence and technology, the partnership between Sonrai and AOA Dx is a significant stride in the development of a scalable, reliable, and ready-for-clinical-use ovarian cancer liquid biopsy test, potentially transforming the medical-conditions landscape and offering significant savings to healthcare systems.
